JLab Hear OTC vs Otofonix Encore

The JLab Hear OTC is a budget-priced OTC hearing aid released in 2024, earning a B grade with a SoundScore of 3.5/5 in our lab testing. At $100, it represents one of the most affordable entry points into the OTC hearing aid market, ranking #36 of 65 devices in its category. This visible-in-ear device delivers a distinctive performance profile with clear strengths and weaknesses. Its standout feature is excellent music streaming quality, scoring 4.6/5—a remarkable 2.68 points above the category average. Feedback handling is equally impressive at 5.0/5, meaning users can expect stable performance without whistling during daily activities. These results suggest JLab leveraged its audio expertise from consumer earbuds in developing this product. However, speech clarity presents challenges. Speech in quiet scored 2.1/5 (0.67 points below category average), while speech in noise scored 1.0/5 (0.46 points below average). Own-voice comfort also measured low at 1.8/5. These limitations are significant for users prioritizing conversation clarity, which is typically the primary reason people seek hearing aids. The JLab Hear OTC is best suited for budget-conscious consumers who value music and media streaming alongside basic amplification, rather than those needing maximum speech intelligibility. Features include rechargeable batteries, iPhone and Android streaming, and hands-free functionality. Buyers seeking stronger speech performance in this price range may want to compare options like the higher-scoring Elehear Beyond or Apple AirPods Pro 2.

The Otofonix Encore is a budget-priced prescription hearing aid available for $295, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This behind-the-ear device ranks #37 of 39 in the Prescription Hearing Aid category, placing it in the bottom tier of its class. In our standardized testing, the Encore demonstrates one clear strength: excellent feedback handling at 4.7/5, which means users are unlikely to experience whistling or squealing during normal use. However, the device shows significant limitations in other areas. Speech intelligibility scores are low in both quiet (1.0/5) and noisy environments (1.0/5), falling 2.40 and 1.11 points below category averages respectively. Music streaming performance scored 0.0/5, indicating this device is not suitable for those who want to stream audio content. The Encore uses disposable batteries and comes in a traditional behind-the-ear style. Notably, our tuned fit testing showed a slight decrease in overall performance compared to the initial fit, with the normalized score dropping from 2.8/5 to 2.4/5. Own-voice comfort also declined substantially when moving to a more occluding coupling. At this price point, consumers may want to consider alternatives. The RxEars Rxi offers substantially better performance at a similar budget price point with a score of 4.07/5. The Otofonix Encore may appeal to buyers seeking a very low-cost entry into prescription hearing aids who prioritize feedback stability, but those needing reliable speech clarity or streaming capabilities should explore other options.